Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EDTCARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update."We had another solid qua ...